Karl Broich

Placebo-controlled studies in depression: necessary, ethical and feasible.

Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach.

Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Regulatory issues in vascular dementia: a European perspective.

Mild cognitive impairment.

Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.

Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective.

Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants.

Biological markers for early detection and pharmacological treatment of Alzheimer's disease.

Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study.

Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.

Anticholinergic drug use and risk for dementia: target for dementia prevention.

Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.

Burnout: a fashionable diagnosis.

Voltage-gated Ca(2+) channel mediated Ca(2+) influx in epileptogenesis.

DSM-5 and clinical trials in psychiatry: challenges to come?

[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.

[Personalised medicine].

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.

Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.

Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease.

The CaV2.3 R-type voltage-gated Ca2+ channel in mouse sleep architecture.

Addressing the regulatory and scientific challenges in multiple sclerosis--a statement from the EU regulators.

Risk of dementia in elderly patients with the use of proton pump inhibitors.

[Safety of medical devices].

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

The European Medicines Agency's strategies to meet the challenges of Alzheimer disease.

Limited effects of an eIF2αS51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease.

Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease.

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

Identification and validation of biomarkers for autism spectrum disorders.

EEG Radiotelemetry in Small Laboratory Rodents: A Powerful State-of-the Art Approach in Neuropsychiatric, Neurodegenerative, and Epilepsy Research.

Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

Drug Regulation and Pricing--Can Regulators Influence Affordability?

Sampling rate, signal bandwidth and related pitfalls in EEG analysis.

The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?

Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data.

The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.

[Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].

Gender-Specific Hippocampal Dysrhythmia and Aberrant Hippocampal and Cortical Excitability in the APPswePS1dE9 Model of Alzheimer's Disease.

Review: Cav2.3 R-type Voltage-Gated Ca(2+) Channels - Functional Implications in Convulsive and Non-convulsive Seizure Activity.

Motor Cortex Theta and Gamma Architecture in Young Adult APPswePS1dE9 Alzheimer Mice.